Literature DB >> 12370512

The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.

Alan Winston1, Sundhiya Mandalia, Deenan Pillay, Brian Gazzard, Anton Pozniak.   

Abstract

The K65R mutation in HIV-1 reverse transcriptase is associated with reduced susceptibility to abacavir and tenofovir. We established its prevalence within a large clinical database, and investigated correlations with other resistance-associated mutations and antiretroviral history. The presence of K65R is associated with previous abacavir use. Although rare, it is preferentially selected within non-thymidine analogue-containing regimens, compared with concurrent zidovudine or stavudine use, which is associated with thymidine analogue mutations. Both genetic routes may compromise abacavir and tenofovir activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12370512     DOI: 10.1097/00002030-200210180-00018

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

1.  In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase.

Authors:  Urvi M Parikh; Dianna L Koontz; Chung K Chu; Raymond F Schinazi; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.

Authors:  Urvi M Parikh; Lee Bacheler; Dianna Koontz; John W Mellors
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.

Authors:  Nicolas Sluis-Cremer; Chih-Wei Sheen; Shannon Zelina; Pedro S Argoti Torres; Urvi M Parikh; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

4.  Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.

Authors:  Jan Weber; Bikram Chakraborty; Jitka Weberova; Michael D Miller; Miguel E Quiñones-Mateu
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

5.  Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.

Authors:  Selwyn J Hurwitz; Raymond F Schinazi
Journal:  Drug Discov Today Technol       Date:  2012

6.  Phylogenetic and genetic analysis of feline immunodeficiency virus gag, pol, and env genes from domestic cats undergoing nucleoside reverse transcriptase inhibitor treatment or treatment-naïve cats in Rio de Janeiro, Brazil.

Authors:  Angelica N Martins; Sheila O Medeiros; Jose P Simonetti; Hermann G Schatzmayr; Amílcar Tanuri; Rodrigo M Brindeiro
Journal:  J Virol       Date:  2008-06-11       Impact factor: 5.103

7.  The renaissance of fixed dose combinations: Combivir.

Authors:  Simon D Portsmouth; Christopher J Scott
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.